Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MAX-10181 combined with temozolomide in high-grade glioma
CTR20252391Phase 2Active
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Aug 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MAX-10181 and temozolomide in glioma, sponsored by Guangzhou Zaiji Medical Technology. Started Aug 2025; status: active.
02
Drugs
MAX-10181temozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on CTR20252391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252391.